CureVac (CDMO Services)
Tubingen, DE
Hybrid — also manufactures internal programs
4 confirmed programs
· 1 sponsors
· Last scored 2026-10-29
75.3
Signal Score
○ FDA Inspections
✓ Clinical Trials (4)
○ SEC Filings
○ Press
✓ EMA GMP (7)
○ MHRA GMP
Quick Facts: CureVac (CDMO Services)
- Signal Score
- 75.3/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean EMA record: 7 active GMP certificates (no deductions)
- Headquarters
- Tubingen, DE
- Modalities
- mRNA
- Active Programs
- 4 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About CureVac (CDMO Services)
mRNA pioneer with CDMO capabilities.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 7 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 7 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates7 on record
Clean EMA record: 7 active GMP certificates (no deductions)
Operations
52.5
4 active programs across 1 sponsors
Modalities: mRNA
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
4 active programs across 1 sponsors · Modalities: mRNA · 1 programs in advanced phases (Phase 2/3)
Programs
4
Sponsors1
ModalitiesmRNA
4 active programs across 1 sponsors
Modalities: mRNA
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT00923312
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV...
PHASE1/PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity
53.0
1 manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Tubingen, Germany
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100
CureVac (CDMO Services) EMA GMP Compliance 7 certificates
2025-11
2025-11
2025-11
2024-12
2023-09
2023-09
2023-05
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| DE_BW_01_GMP_2026_0102 | CureVac Manufacturing GmbH | Germany | 2025-11-13 | COMPLIANT |
| DE_BW_01_GMP_2026_0103 | CureVac Manufacturing GmbH | Germany | 2025-11-13 | COMPLIANT |
| DE_BW_01_GMP_2026_0101 | CureVac Manufacturing GmbH | Germany | 2025-11-13 | COMPLIANT |
| DE_BW_01_GMP_2025_0094 | CureVac Manufacturing GmbH | Germany | 2024-12-17 | COMPLIANT |
| DE_BW_01_GMP_2024_0013 | CureVac Manufacturing GmbH | Germany | 2023-09-28 | COMPLIANT |
| DE_BW_01_GMP_2024_0012 | CureVac Manufacturing GmbH | Germany | 2023-09-28 | COMPLIANT |
| DE_BW_01_GMP_2023_0203 | CureVac RNA Printer GmbH | Germany | 2023-05-23 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Clinical Activity 4 studies
NCT07073183
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With...
PHASE1
Withdrawn
NCT03291002
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
PHASE1
Unknown
NCT01915524
Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV...
PHASE1
Terminated
NCT00923312
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell...
PHASE1/PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business, and we can't yet tell which of those roles belong to it. Why: the board covers the whole group and doesn't say which business unit a role belongs to. We'd rather show no number than one that isn't really this company's.
Source:
career.curevac.com
· Checked Nov 20, 2026
Frequently Asked Questions About CureVac (CDMO Services)
Does CureVac (CDMO Services) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 7 EMA GMP certificates for CureVac (CDMO Services).
How many clinical programs is CureVac (CDMO Services) linked to?
CureVac (CDMO Services) is associated with 4 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is CureVac (CDMO Services)'s CDMO Signal Score?
CureVac (CDMO Services) has a Signal Score of 75/100, based on quality, operations, financial stability, and capacity data.
Evaluating CureVac (CDMO Services) for a manufacturing program?
Use the free AI matchmaker to compare CureVac (CDMO Services) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 82.9
Recombinant Protein, Plasmid DNA, mRNA, Microbial Fermentation
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Signal Score: 82.1
mRNA
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.9
mRNA, Biologics, Cell Therapy
Ethris
Planegg, DE
Signal Score: 56.5
mRNA
Compare CureVac (CDMO Services) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.